Affordable Access

Publisher Website

Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score

Clinica Chimica Acta
Publication Date
DOI: 10.1016/j.cca.2007.04.002
  • Bnp
  • Crp
  • Trs
  • Stemi
  • Biology


Abstract Background In ST-elevation myocardial infarction (STEMI) B-type natriuretic peptide (BNP) holds promise for risk stratification. Aim of this study was to assess prognostic value of plasma BNP measurement and to compare with other powerful prognostic markers — TIMI Risk Score (TRS) and C-reactive protein (CRP) in patients with first STEMI treated with primary PCI (pPCI). Methods 86 patients, admitted within initial 12 h of the first STEMI. Admission plasma levels of BNP were measured by MEIA method. Serum levels of CRP were measured using immunoturbidimetric assays. Composite end point (CEP) was assessed after 7 months. Results Median plasma BNP value was higher in patients with CEP, compared with those without CEP ( p < 0.001). Patients with plasma BNP > 99.2 pg/mL were at significantly higher risk for CEP (the highest sensitivity and specificity). CRP level > 10.6 mg/dL was also associated with poor outcome. TRS has not influenced the occurrence of CEP. In the analysis of logistic regression the BNP value > 99.2 pg/mL was the strongest predictor of CEP. ROC analysis identified BNP measurement as significant to estimate adverse outcome 0.950 in the prediction of CEP (95% Confidence interval = 0.878–0.985). Conclusion Admission plasma BNP concentrations provide incremental prognostic information in patients with first STEMI treated with pPCI.

There are no comments yet on this publication. Be the first to share your thoughts.